MedTrace Logo

Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification

NCT03638726 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-10-09

No results posted yet for this study

Summary

Mydriatic eye drops are routinely used before phacoemulsification but they are not free of drawbacks. Several alternatives were tried to overcome their limitations.

Conditions

  • Cataract
  • Mydriasis
  • Adverse Drug Event

Interventions

DRUG

Atropine sulfate and epinephrine

Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.

DRUG

Topical cyclopentolate and phenylephrine

Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.

Sponsors & Collaborators

  • Dar El Oyoun Hospital

    lead OTHER

Principal Investigators

  • Nossair · Dar El Oyoun Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2019-03-31
Completion
2019-06-30
FDA Drug
Yes

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03638726 on ClinicalTrials.gov